Lantern Pharma (LTRN) News Today $2.94 -0.14 (-4.55%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Lantern Pharma doses first patient in LP-300 trial expansion cohortNovember 20 at 5:57 PM | markets.businessinsider.comLTRN: Pediatric Rare Cancer in FocusNovember 12, 2024 | finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comLantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...November 9, 2024 | finance.yahoo.comLantern Pharma Inc. (LTRN) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comLantern Pharma Advances AI-Driven Cancer TherapiesNovember 8, 2024 | markets.businessinsider.comLantern Pharma Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 7, 2024 | businesswire.comStarlight Therapeutics Announces Inaugural Members of Scientific Advisory BoardNovember 5, 2024 | finance.yahoo.comLantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ETOctober 31, 2024 | businesswire.comLantern Pharma to Host & Participate in Two Public Webinars During OctoberOctober 21, 2024 | finance.yahoo.comLantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDAOctober 15, 2024 | finance.yahoo.comLantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...October 9, 2024 | finance.yahoo.comLantern Pharma (NASDAQ:LTRN) Stock, Insider Trading ActivityOctober 9, 2024 | benzinga.comLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s CancersSeptember 24, 2024 | finance.yahoo.comLantern Pharma Gets Three FDA Rare-Pediatric Designations for LP-184September 23, 2024 | marketwatch.comLantern Pharma Says FDA Oks Rare Pediatric Disease Designations In MRT, RMS, And HepatoblastomaSeptember 23, 2024 | markets.businessinsider.comLantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children's CancersSeptember 23, 2024 | tmcnet.comLantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a MillionaireAugust 31, 2024 | msn.comLTRN: Second Quarter ResultsAugust 12, 2024 | msn.comLantern Pharma Inc. (LTRN) Q2 2024 Earnings Call TranscriptAugust 11, 2024 | seekingalpha.comLantern Pharma Reports Second Quarter 2024 Financial Results and Business UpdatesAugust 9, 2024 | tmcnet.comLTRN Stock Earnings: Lantern Pharma Beats EPS for Q2 2024August 8, 2024 | investorplace.comLTRN: Harmonic Clinical UpdateAugust 6, 2024 | msn.comLTRN Aug 2024 2.000 putAugust 5, 2024 | ca.finance.yahoo.comLantern Pharma Inc. (NASDAQ:LTRN) Sees Significant Decline in Short InterestLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the recipient of a large drop in short interest in June. As of June 15th, there was short interest totalling 333,500 shares, a drop of 20.6% from the May 31st total of 419,800 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 163,200 shares, the short-interest ratio is presently 2.0 days.June 29, 2024 | marketbeat.comLantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284June 12, 2024 | businesswire.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Aaron G.L. Fletcher Sells 10,000 SharesMay 29, 2024 | insidertrades.comLantern Pharma Inc. (NASDAQ:LTRN) Major Shareholder Sells $62,500.00 in StockLantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) major shareholder Aaron G.L. Fletcher sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $6.25, for a total value of $62,500.00. Following the transaction, the insider now owns 59,326 shares of the company's stock, valued at $370,787.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.May 28, 2024 | marketbeat.comThe 3 Best Machine Learning Stocks to Quadruple Your Money by 2035May 23, 2024 | investorplace.comLTRN: Expanding Horizons into AsiaMay 14, 2024 | finance.yahoo.comLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsMay 9, 2024 | businesswire.comOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismMay 6, 2024 | businesswire.comLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETMay 2, 2024 | businesswire.com3 Machine Learning Stocks with the Potential to Make You an Overnight MillionaireMay 1, 2024 | investorplace.comH.C. Wainwright Keeps Their Hold Rating on Lantern Pharma (LTRN)April 25, 2024 | markets.businessinsider.comLantern Pharma (NASDAQ:LTRN) Given Neutral Rating at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Lantern Pharma in a research note on Thursday.April 25, 2024 | marketbeat.comLantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 24, 2024 | finance.yahoo.comLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentApril 24, 2024 | businesswire.comLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanApril 22, 2024 | businesswire.comLantern Pharma Inc. (LTRN)April 17, 2024 | finance.yahoo.comLantern Pharma Inc Ordinary SharesApril 13, 2024 | morningstar.comLantern Pharma (NASDAQ:LTRN) Trading Down 13.8%Lantern Pharma (NASDAQ:LTRN) Stock Price Down 13.8%April 12, 2024 | marketbeat.comShort Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Expands By 191.1%Lantern Pharma Inc. (NASDAQ:LTRN - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 420,900 shares, a growth of 191.1% from the March 15th total of 144,600 shares. Based on an average daily volume of 276,000 shares, the days-to-cover ratio is presently 1.5 days. Currently, 5.3% of the shares of the stock are sold short.April 12, 2024 | marketbeat.comLantern Pharma Inc (LTRN)April 10, 2024 | investing.comLantern Pharma Inc. to Post FY2024 Earnings of ($2.06) Per Share, HC Wainwright Forecasts (NASDAQ:LTRN)Lantern Pharma Inc. (NASDAQ:LTRN - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Lantern Pharma in a report released on Tuesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.06) perMarch 21, 2024 | marketbeat.comLantern Pharma Inc. (LTRN) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | seekingalpha.comLantern Pharma Inc. (NASDAQ:LTRN) Expected to Earn Q1 2024 Earnings of ($0.43) Per ShareLantern Pharma Inc. (NASDAQ:LTRN - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 EPS estimates for Lantern Pharma in a report issued on Tuesday, March 19th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.43) for the quaMarch 20, 2024 | marketbeat.comLTRN: 2023 ResultsMarch 19, 2024 | msn.comH.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)March 19, 2024 | markets.businessinsider.comLantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.com Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Top "Sleeping Giant" Crypto In The Market Now (Ad)Top "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late LTRN Media Mentions By Week LTRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LTRN News Sentiment▼1.000.45▲Average Medical News Sentiment LTRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LTRN Articles This Week▼41▲LTRN Articles Average Week Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TNXP News BTAI News PRPH News LPTX News OTLK News PLX News TELO News CNTX News VTYX News RPTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LTRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
